Business Wire

KIAEL Awarding Committee Lauds Transformative WCECCE Conclusions

23.11.2022 08:00:00 EET | Business Wire | Press release

Share

The Awarding Committee members of the Khalifa International Award for Early Learning (KIAEL) this week commended UNESCO’s Tashkent Declaration for Early Childhood Education’s call to highlight the themes of sustainability and climate change among the core guiding principles as knowledge drivers for the transformation of early childhood care and education (ECCE) systems globally.

“We are delighted that representatives of 150 countries who participated at the recent World Conference on Early Childhood Care and Education in Uzbekistan endorsed the guiding principles of the Tashkent Declaration. They have placed strong emphases on the right of every child to access quality ECCE services; the development of the ECCE workforce; innovation to transform ECCE; and a whole-of-government, multi-sectoral and integrated approach to ECCE,” said conference attendee, Dr. Nirmala Rao, a Chair Professor at the Faculty of Education at the University of Hong Kong and Serena H C Yang Professor in Early Childhood Development and Education.

Dr. Rao is one of five Awarding Committee members of the KIAEL.

The KIAEL has two categories; Best Research & Studies and Best Programmes & Teaching Practices. The deadline for applications is the 28th of February 2023. Applications need to be submitted through the online application system at https://el.khaward.ae/ before the deadline.

“Our mission is to identify and reward both research on early childhood education and care that supports improvements in practice and exemplary programmes or teaching practices demonstrated to improve quality and/or the learning and development of the young children served,” said Dr. Barnett, founding Co-Director of the National Institute for Early Education and Board of Governors Professor of Education at Rutgers University.

"All programs submitted for consideration by the KIAEL awarding committee would have been subject to an evaluation of implementation or outcomes that provide evidence of implementation and potential or documented impacts on practice in early learning and on early learning outcomes,” said Professor Iram Siraj, Professor of Child Development and Education, University of Oxford.

The KIAEL Awarding Committee will select two winners for each award with a cash prize of USD 50,000 for each winner.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lejo Johnny
Leidar MENA
Mobile: +971504537023
E-mail: lejo.johnny@leidar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 09:30:00 EET | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In DESTINY-Breast05, Enhertu significantly reduced the risk of in

Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 09:00:00 EET | Press release

Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare

LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 06:30:00 EET | Press release

LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t

DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 23:30:00 EET | Press release

DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, improving data accessibility and managing long-term costs. Built for data-intensive research, high-performance computing and AI workloads, DDN EXAScaler

Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 17:15:00 EET | Press release

TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wrong about the agent's own work. In CXBench, a benchmark of LLM agents in regulated customer-experience workflows published in October 2026, 80.1% of runs that reached the right outcome still failed the process checks, and only 13.8% passed b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye